It has been recently reported that cannabinoid and GABA systems in the nucleus accumbens (NAc) are involved in anxiety-related behaviors. Thus the purpose of the present study is to investigate the involvement of ACPA interaction with GABA-ergic of the NAc shell in anxiolytic-like behaviors in Wistar male rat. The elevated plus maze apparatus has been used to test parameters of anxiety-like behaviors. The data demonstrated that bilateral injection of GABA (A) receptor agonist (Muscimol 0.4 μg/μl) increased % OAT. Furthermore, injection of GABA (A) receptor antagonist (Bicuculline 0.9μg/μl) increased locomotor activity. The data indicated anxiolytic-like behaviors caused by the Muscimol injection into the NAc shell. Moreover, bilateral injection of ACPA (CB1 -selective agonists; 0.025μg/μl) into the NAc shell induced anxiogenic-like behaviors. The final results showed that intra-NAc shell injection of subthreshold dose of Muscimol (0.2 μg/μl) attenuated anxiogenic-like behaviors by higher dose (0.025 μg/μl) of ACPA in the NAc shell. In addition, intra-NAc shell injection of subthreshold dose of Bicuculline (0.6 μg/μl) did not alter anxiogenic response by ACPA administration in the NAc shell. The results suggested that the activation of the NAc shell GABA (A) receptor attenuated the activity of cannabinoid system in the NAc shell.
INTRODUCTION
There are different investigations indicating neurobiology of anxiety and drugs that induced anxiety-like behaviors in different brain regions (Zarrindast, Nasehi et al., 2010; Nasehi, Mafi et al., 2011; . Although, traditionally, the NAc shell has been considered a region involved in defensive and anxiety-like behaviors (Martinez, Ropero et al., 2002; Avena, Rada et al., 2008) ; (Pliakas, Carlson et al., 2001) ; (Reynolds and Berridge 2003) (da Cunha, Lopes et al., 2008) , locomotion (Gargiulo 1996) (Martinez, Ropero et al., 2002) and depression (Shirayama and Chaki 2006) . Endocannabinoids (ECS ) comprise a family of eicosanoid and related unsaturated fatty acid derivatives (Devane, Hanus et al., 1992) , that have been implicated in the regulation of a range of physiological processes including anxiety (Chaperon and Thiebot 1999) , neural development (Fride 2008) , immune function (Stella 2009 ), pain (Guindon and Hohmann 2009) , emotional state (Lutz 2009 ), synaptic plasticity and learning (Heifets and Castillo 2009) .
Two mammalian cannabinoid receptors, CB1 and CB2, are both coupled to similar transduction systems through Gi or Go proteins. (Pertwee and Ross 2002) . In addition, CB1 receptors are found on axons and axon terminals (Egertova and Elphick 2000) (Rodriguez, Mackie et al., 2001) , predominantly in the central and peripheral nervous system, where they have been implicated in presynaptic inhibition of transmitter release in different brain regions (Howlett, Barth et al., 2002) , such as Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline, dopamine, 5-HT, cholecystokinin, glutamate, D-aspartate and glycine. (Howlett 2002) (Hajos, Katona et al., 2000) (Freund, Katona et al., 2003) . Arachidonylcyclopropylamide (ACPA) is one of the CB1-selective agonists (Hillard, Manna et al., 1999) . CB1 receptors are expressed in high density in key regions implicated in the regulation of anxiety such as the amygdala, hippocampus, anterior cingulate cortex, prefrontal cortex and the nucleus accumbens ( (Katona, Rancz et al., 2001; Manzoni and Bockaert 2001, Ameri 1999) .
GABA is the main central inhibitory neurotransmitter in different brain regions. It's receptors in the brain have been classified as GABA (A), GABA (B) and GABA (C) (Bormann 2000) . The involvement of GABA receptors in modulatory of anxiety has been the subject of extensive studies. (Lopes, Ganzer et al.; Lopes, da Cunha et al., 2007) . Furthermore, GABA-ergic neurons throughout the CNS express high levels of CB1 receptor immunoreactivity, advancing the notion that cannabinoid and GABA receptors interact to mediate a number of pharmacological endpoints (Marsicano and Lutz 1999) . The vast majority of cells in the nucleus accumbens contain GABA-ergic medium-spiny interconnected by a dense network of recurrent collaterals (Pennartz, Groenewegen et al., 1994) , and innervated by inhibitory GABA-ergic interneurons (Koos and Tepper 1999) .
One of the animal models for the study of anxiolytic or anxiogenic drugs is elevated plus-maze (EPM) (Pellow and File 1986) . Several reports have indicated that EPM task retains as a reliable and suitable animal model to assess the neurobiology of anxiety-related (both anxiolytic and anxiogenic-like) and emotional behavior. (Pellow, Chopin et al., 1985; Carobrez and Bertoglio 2005; Walf and Frye 2007; Nasehi, Piri et al., 2010; Zarrindast, Mahboobi et al., 2011; .
Because of high density of GABA receptors and the extensive co-localization of CB1 and GABA in the the NAc shell (Cheer, Wassum et al., 2006) (Lopes, da Cunha et al., 2007) , in the present study, we investigated the possible involvement of CB1 receptor ag-onist (ACPA) in GABA-ergic receptor agonist-induced anxiolytic effect.
MATERIALS AND METHODS

Animals
Male Wistar rats weighing 240 -280g (2-montht age, the Institute of cognitive science, Tehran, Iran), at the time of surgery were housed in groups of 5-6 rats/cage with free access to food and water in a room with a 12:12 h light/dark cycle (lights on at 07.00h), and controlled temperature (23±1 ۫C).The animals were only handled for weighing, drug administration and cage cleaning. All experiments were performed between 09.00h and 14.00h, and each rat was tested only once. Eight animals were used in each experimental group.
Surgery
Animals were anaesthetized using a ketamine hydrochloride (50 mg/kg) plus xylazine (5 mg/kg) solution .They were then positioned in a stereotaxic frame (Stoelting Co, Illinois, USA) in flat-skull position. A midline incision was made in the skin of the skull, and then the underlying periosteum was retracted. A stainless steel guide cannulae (22 gauge) was implanted (bilaterally) 2mm above the NAc shell region corresponding in rats' brain stereotaxic atlas (Paxinos and Watson 2007) . Stereotaxic coordinates for the NAc shell was 1.2mm posterior to bregma, ±0.9 mm lateral to the midline and -5.3mm ventral of the dorsal surface of the skull. The inserted cannulae were secured to the bone with dental acrylic cement. A styled was introduced into the guide cannula to prevent possible obstruction. All animals were allowed about 5-7 days to recover from surgery and the effect of the anesthetic agents.
Drug microinjections
Microinjections were given through the indwelled cannula (27-gauge, Supa; Iran), terminating 2mm below the ventral tip of the guiding cannulae, connected to a Hamilton microsyringe (2.5 µl) via polyethylene tubing.
The injected volume (0.6µl/rat) was administered bilaterally over a period of 60s. Further 60s was allowed for the solution to diffuse. Testing sessions were always performed 5 min after intra-NAc shell injections.
Behavioral test (elevated plus-maze)
The elevated plus-maze (EPM) consisted of four arms, two of which had no side or end walls (open arms; 50×10cm). The other two had side walls and end walls, but were open on the top (closed arms; 50×10×40cm). Where the four arms intersected, there was a square platform of 10×10cm.
5-7 days after the surgery, the effects of intra-NAc shell injections of drugs were tested in the EPM. Rats were placed in the experimental room at least 1h before testing. Animals were randomly assigned to treatment conditions and tested in a counter-balanced order. Rats were individually placed in the center of the maze facing a closed arm and were allowed 5min of free exploration.
The number of entries into open or closed arms and the total time spent in the open or closed arms were recorded by means of a digital camera, while a monitor and a computer-recording system were installed in an adjacent room. The test room was illuminated by two 60W bulbs located 1.5m above the apparatus. Raw data were used to manually calculate indices corresponding to the anxiety-like behaviors. Entries were defined when all four paws were in the arms and measured by a hand counter.
The percentage open arm entries as well as the open arm time percentage (as standard anxiety-like behavior indices) were calculated as follows: (a) % OAT (the ratio of time spent in open arms to total time spent in any arm×100); (b) %OAE (the ratio of entries into open arms to total entries×100) (Zarrindast, Torabi et al., 2006; Zarrindast, Valizadegan et al., 2008; Nasehi, Mafi et al., 2011) . (c) Total closed and open arm entries were considered as a relatively pure index of locomotor activity (Zarrindast, Solati et al., 2008; . Drugs which affect anxiety-like behaviors may either increase or decrease % OAT and %OAE, indicating anxiolytic-like or anxiogenic-like responses, respectively. Experiments were performed by someone bled to responses, asswssment outcomes and statistical analyses.
Drugs
Drugs used in the present study were muscimol (as selective GABA (A) receptor agonist, Tocris Cookson, Bristol, UK), bicuculline (as selective GABA (A) receptor antagonist, Tocris Cookson, Bristol, UK), ACPA (as CB1-selective agonists, Tocris Cookson, Bristol, UK) . The researchers in the current study used ketamine and xylazine (Alfasan Chemical Co, Woerden, and Holland) for induction and maintenance of anesthesia during the surgical procedures. All drugs were dissolved in sterile 0.9% saline just before the experiment. Control animals received either saline. Drugs and saline were injected intrashell NAc in a volume of 0.6μl /rat.
Drug treatments
Experiment 1: effects of intra-NAc shell muscimol administration on anxiety-like behaviors in the presence or absence of bicuculline. In this experiment, seven groups of animals were used and all injections were done into the NAc shell. The first four groups of rats received saline (0.6 μl/rat) or different doses of Muscimol (0.1, 0.2 and 0.4 μg/μl). Another three groups of animals received different doses (0.3, 0.6 and 0.9 μg/μl) of Bicuculline Testing sessions were carried out 5min after the injection.
Experiment 2: effects of intra-NAc Shell administration of ACPA on anxiety-like behaviors in the presence or absence of GABA)A( system drugs). In this experiment, ten groups of animals were used and all injections were done into the NAc shell. The first four groups of rats received saline (0.6μl/rat) or different doses of ACPA (0.00625, 0.0125 and 0.025 μg/ μl). Next three groups of animals received three doses (0.00625, 0.0125 and 0.025 μg/ μl) of ACPA, 5min before subthreshold doses of Muscimol (0.2 μg/μl). The remaining three groups of animals received doses of ACPA (0.00625, 0.0125 and 0.025 μg/ μl), 5min before subthreshold doses of Bicuculline (0.6 μg/μl). The testing sessions were performed 5min after the final injection.
Histology
At the end of the study, in order to verify the accuracy of the injection sites, 0.6 µl/rat of 1% methylene blue solution were injected into the NAc shell. Animals' brains were then removed and placed in formaldehyde (10%). After several days, brains were sliced by vibro-slice apparatus in transverse plane (40 µm). Cannulae placements were verified based on the corresponding atlas of Paxinos and Watson (Paxinos and Watson 2007) . Data from rats with misplaced cannulae in the NAc shell were excluded from the analyses.
Statistical analysis
Given the data normality of distribution and homogeneity of variance, the results were statistically evaluated by one-way ANOVA to compare the effects of different doses of each drug with the corresponding control group. Meanwhile two-way ANOVA was used to evaluate the interactions between the drugs. Following a significant F-value, post-hoc analysis (Tukey test) was performed to assess the specific group comparisons. In all comparisons, P<0.05 indicated a statistical significance. 
RESULTS
The
DISCUSSION
The nucleus accumbens functions to gate emotional and motivational response. Moreover, NAc shows high levels of central cannabinoid receptor1 (CB1) expression (Cheer, Wassum et al., 2006) . Manipulation of CB1 signaling within the NAc triggers robust emotional/motivational alterations (Winters, Kruger et al.) (Shinohara, Inui et al., 2009 ). Furthermore, GABA (A) and GABA (B) systems have been suggested to play an important role in the modulation of anxiety (Crestani, Keist et al., 2002) (Kash, Tecott et al., 1999; Rudolph, Crestani et al., 1999; Sasaki, Fan et al., 2002) (Cryan, Kelly et al., 2004; Cryan and Kaupmann 2005) ; (Jacobson, Bettler et al., 2007) . Along this line, activation of GABA (A), but not GABA (B) receptor, demonstrated anxiolytic effects (Sanders and Shekhar 1995; Zarrindast, Rostami et al., 2001 ). Whereas, some other studies have shown that, the fear/ anxiogenic effect associated with GABA (A) receptor activation (Reynolds and Berridge 2001) .
In the present study, the researchers tried to investigate the role of intra-NAc shell GABA (A) receptor agonist and antagonist administration in anxiogenic-like behaviors induced by ACPA injection in this region, using the EPM task. Figure 2 . effects of intra-NAc shell injection of ACPA alone or in combination with Muscimol and Bicuculline on anxiety-like behaviors. Rats were injected with saline (0.6 μl/rat), ACPA (0.00625, 0.0125 and 0.025 μg/ μl), and also coadministration of Muscimol (0.2 μg/μl) or Bicuculline (0.6 μg/μl),5min after injection of ACPA (0.00625, 0.0125 and 0.025 μg/ μl) . The injected volumes for all drugs were (0.6µl intra-NAc shell) bilaterally. Tests were performed 5min after final intra-NAc shell injection. Each bar represents mean±S.E.M. %OAT (A), %OAE (B) or locomotor activity (C). N = 8. *P<0.05, when compared to the saline treated rats. +P<0.05 when compared to ACPA (0.00625, 0.0125 and 0.025 μg/ μl ) treated rats.
The effects of GABA (A) system in the NAc shell on anxiety-like behaviors
There are different reports describing anxiolytic/anxiogenic effects by administration of GABA (A) and GABA (B) agonists in NAc shell. GABA (A) and GABA (B) agonists microinjection into the NAc shell in both free-feeding animals (Lopes, da Cunha et al., 2007) and food-deprived rats (Lopes, Ganzer et al.) induced anxiolysis in an animal model of anxiety. In addition, injection of Muscimol into the NAc shell evoked a strong defensive burying or paw-treading behavior (Reynolds and Berridge 2001) . However, some other investigations have reported the opposite. A fear/anxiogenic response was observed after GABA(A) injection in the rostral parts of NAc shell (Reynolds and Berridge 2001) . To this end, the researchers targeted the GABA (A) receptor family, which has a pivotal role in controlling the stress conditions in human and laboratory animals. The data demonstrated that, intra-NAc shell injection of GABA(A) receptor agonist (Muscimol) increased the %OAT, while it did not alter %OAE and locomotor activity, indicating anxiolytic-like effects exerted by the Muscimol administered into this region. Variations in anxiolytic/ anxiogenic response observed between the present study and some reports can possibly be attributed to different microinjection sites (rostral, medial and caudal) of NAc (Lopes, Ganzer et al.) , different laboratory settings and might also partly be attributed to doses of the GABA-ergic agents. The present study postulated the neutral effect of intra-NAc shell Bicuculline (selective GABA A receptor antagonist) injection. It did not alter %OAT and %OAE, but increased locomotor activity at applied doses. Infusion of Bicuculline in the rostral part of preoptic area induced most robust locomotor activivation. In contrast, bicuculline infused into other forebrain structures, including the bed nucleus of stria terminalis, caudate-putamen, globus pallidus, sublenticular extended amygdala, did not produc significant locomotor activation (Zahm, Schwartz et al.) . Furthermore, to the best of our knowledge, there is a report indicating that, both GABA (A) and GABA (B) antagonists injected into the NAc shell did not affect the anxiety-like behaviors (Lopes, Ganzer et al.) .
The effect of intra-NAc shell ACPA administration on GABA (A) system agents on anxiety-like behaviors It has long been recognized that cannabis produces a bimodal effect on anxiety in humans, with low doses having anxiolytic and high doses having anxiogenic effects (Dannon, Lowengrub et al., 2004) . Similar biphasic effects on anxiety-like behaviors by the administration of cannabinoid agonists have been reported in rats and mice (Viveros, Marco et al., 2005) . There are some possible explanations about the mechanisms contributing to biphasic effects of cannabinoid agonists. Distinct receptors (CB1 receptors vs. novel non-CB1 cannabinoid sensitive receptors ) with a differential sensitivity in the inhibitory/anxiogenic and the stimulatory/ anxiolytic effects are implicated for these compounds (Viveros, Marco et al., 2005) (Haller, Bakos et al., 2002) . In addition, it is variated in a region-dependent manner, with anxiolytic-like effects produced in the prefrontal cortex, ventral hippocampus and periaqueductal gray (Lisboa, Resstel et al., 2008; Rubino, Realini et al., 2008) and anxiogenic-like effects produced in dorsal hippocampus and amygdala (Roohbakhsh, Moghaddam et al., 2007) . Based on our findings, intra-NAc shell administration of ACPA (CB1 -selective agonists) at 0.025 μg/μl dose decreased the % OAT, while it did not alter % OAE and locomotor activity, indicating anxiogenic-like effects exerted by the ACPA administered into this region. The result suggested the anxiogenic-like effects of CB1 -selective agonist injection in the NAc shell, which had been supported by some previous studies. Several investigations have assessed the interaction between the GABA-ergic and canabenoid systems in regulating blood pressure (Dean) , locomotion ( (Romero, Garcia-Palomero et al., 1996) and anxiety (Antonelli, Tomasini et al., 2009 ) in different brain regions. Activation of CB1 receptor disrupts a balance between excitatory and inhibitory systems (Petroff 2002) . Presynaptic CB1 receptors to GABA-ergic interneurons in the hippocampus reduce GABA, and may modulate GABA-ergic function (Muntoni, Pillolla et al., 2006) (Arevalo, de Miguel et al., 2001) (van der Stelt and Di Marzo 2003) . (Hoffman and Lupica 2000) . In contrast, CB1 receptors agents affect extracellular dopamine (Melis, Succu et al., 2007) , inhibits glutamate release (Xi, Gilbert et al., 2006) , and have synergistic interaction with mu opioid to release GABA via a disinhibitory mechanism on local GABA (A) receptormediated in the nucleus accumbens (Pickel, Chan et al., 2004) (Sperlagh, Windisch et al., 2009) (Gonzalez, Paz et al., 2009 ). The CB1 receptors activation (selectively expressed in a subset of GABA-ergic inhibitory interneurons) reduces GABA release from presynaptic terminals, thereby increasing the excitability of principal pyramidal cells (Viveros, Marco et al., 2005) . The literature also reveals that, the sub-threshold dose of muscimol decreased response induced by the higher intra-NAc shell ACPA dose. Comparing the results obtained from the present study and some previous reports, it is speculated that these controversial interactions due to involving the benzodiazepine/GABA (A) receptor in both the anxiogenic and the anxiolytic reactions of cannabinoid agonists (Viveros, Marco et al., 2005) . In addition, intra-NAc shell injection of the sub-threshold dose of bicuculline did not alter anxiogenic response induced by the intra-NAc shell injection of ACPA.
CONCLUSION
In summary, the researchers' investigation showed that: 1) activation of GABA (A) receptor in the NAc shell induced anxiolyticlike behaviors, 2) administration of Bicuculline into the NAc shell did not alter anxietylike behaviors, but increased locomotor activity. 3) intra-NAc shell administration of ACPA, induced anxiogenic-like behaviors. 4) intra-NAc shell injection of muscimol attenuated the anxiogenic-like behaviors induced by intra-NAc shell injection of ACPA. and 5) intra-NAc shell injection of the sub-threshold dose of Bicuculline did not alter anxiogeniclike behaviors induced by the intra-NAc shell ACPA. Finally, it seems that the activation of the NAc shell GABA (A) receptor attenuated the activity of cannabinoid system in the NAc shell.
